Treatment Algorithms in Triple-Negative Breast Cancer: How to Apply them to Clinical Practice

home / treatment-algorithms-with-the-oncology-brothers / treatment-algorithms-in-triple-negative-breast-cancer-how-to-apply-them-to-clinical-practice

The Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, are joined by Ruth M. O'Regan, MD, and Anna Weiss, MD, to discuss treatment algorithms in triple-negative breast cancer.

Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides

EP. 1: Treating Early-Stage Node-Negative Triple-Negative Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Ruth M. O'Regan, MD;Anna Weiss, MD
January 24th 2024

Ruth M. O'Regan, MD, and Anna Weiss, MD, join the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of early-stage node-negative triple-negative breast cancer (TNBC).

Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides

EP. 2: Therapeutic Approaches for High-Risk or Locally Advanced TNBC

Rahul Gosain, MD;Rohit Gosain, MD;Ruth M. O'Regan, MD;Anna Weiss, MD
January 24th 2024

The expert panel provides clinical insights on treating patients with high-risk or locally advanced triple-negative breast cancer.

Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides

EP. 3: Clinical Insights on Treating Metastatic Triple-Negative Breast Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Ruth M. O'Regan, MD;Anna Weiss, MD
January 24th 2024

Ruth M. O’Regan, MD, and Anna Weiss, MD, discuss treatment paradigms for patients with metastatic triple-negative breast cancer and the role of surgery.

Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides

EP. 4: Supportive Care and Managing Toxicities Related to ADCs in TNBC

Rahul Gosain, MD;Rohit Gosain, MD;Ruth M. O'Regan, MD;Anna Weiss, MD
January 24th 2024

A panel of medical oncologists provides insights on managing toxicities in patients with triple-negative breast cancer who are receiving antibody-drug conjugates.